摘要
Abstract
Objective:To investigate the clinical effect of first-line chemotherapy regimen Pemetrexed and Cisplatin combined with Osimertinib in advanced non-small cell lung cancer patients.Method:From January 2021 to June 2023,90 patients with advanced non-small cell lung cancer admitted to Zibo Shibo High-tech Hospital were divided into control group(given Pemetrexed combined with Cisplatin,45 cases)and observation group(given Pemetrexed combined with Cisplatin and Osimertinib,45 cases).The total response rate,serum tumor markers[cancer antigen 153(CA153),alpha fetoprotein(AFP),vascular endothelial growth factor(VEGF),cytokeratin 19 soluble fragment antigen 21-1(CYFRA21-1)],adverse reactions,and 6-month progression free survival rate were compared between the two groups.Result:The total remission rate in the observation group was 71.11%,which was higher than 48.89%in the control group(P<0.05).Before treatment,there was no difference in the expression of serum tumor markers between the two groups(P>0.05).After treatment,the expression of serum CA153,AFP,VEGF and CYFRA21-1 in the two groups were down regulated,and the expression levels of various indicators in the observation group were lower than those in the control group(P<0.05).The adverse reaction rate of the observation group was 28.89%,and the 6-month progression free survival rate was 51.11%,which had no statistical significance compared with 22.22%and 35.56%in the control group(P>0.05).Conclusion:In patients with advanced non-small cell lung cancer,the combination of Osimertinib,Pemetrexed and Cisplatin can further down-regulate the expression of serum tumor markers,promote disease remission,and no serious adverse reactions have occurred,with high safety.关键词
晚期非小细胞肺癌/奥希替尼/培美曲塞/顺铂/肿瘤标志物/不良反应Key words
Advanced non-small cell lung cancer/Osimertinib/Pemetrexed/Cisplatin/Tumor markers/Adverse reactions
